SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Steve Fancy who wrote (6011)1/28/1999 9:41:00 AM
From: Bhag Karamchandani  Read Replies (1) of 6136
 
Steve: Did you consider writing covered calls- open for Feb. onwards. I saw strike prices of 60 and 65? Since you play the option angle I
was wondering if you would care to share your insights as to why you sold out.

PS $60 per share sale price suggests that AGPH management discounted the present value of their research /oncology div. as near zero. In a way, this is confirmed by WAL share price appreciating after their offer.
I am disappointed for AGPH shareholders- based on the information publicly available.

Another enigma: Why did AGPH not consider alternative offers. Was it because WAL offered the most autonomy for the AGPH Division ( after the merger)?? If so, this may be in the best interest of AGPH management but not necessarily shareholders.

Finally, I dropped out of this thread when I found some shareholders, who actively post, acting like IR proxies- rather than owners of a company. Nevertheless, I learnt a lot on this thread.

Good Luck to you.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News